scholarly journals Prevalence of antibiotic resistance among clinical isolates of Kleibsiella pneumoniaeisolated from a Tertiary Care Hospital in Pakistan.

2009 ◽  
Author(s):  
Amin, A. ◽  
Ghumro, P. B. ◽  
Hussain, S. ◽  
Hameed, A.
Keyword(s):  
Antibiotic Resistance ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Clinical Isolates ◽  
Care Hospital

scholarly journals Current Pattern of Antibiotic Resistance in Clinical Isolates of Acinetobacter Baumannii from Intensive Care Units of Tertiary Care Hospital

2016 ◽  
Vol 22 (1) ◽  
pp. 17 ◽  
Author(s):  
Ishrat Irfan Ali ◽  
Irfan Ali Khan ◽  
Muhammad Kashif Munir ◽  
Sheikh Ajaz Rasool
Keyword(s):  
Antibiotic Resistance ◽  
Intensive Care ◽  
Acinetobacter Baumannii ◽  
Intensive Care Units ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Clinical Isolates ◽  
Hospital Environment ◽  
Care Hospital ◽  
Acinetobacter Spp

<p><strong>Abstract</strong></p><p><strong>Purpose:  </strong>To determine the pattern of antibiotic resistance in clinical isolates of Acinetobacter baumannii from ICU’s of tertiary care hospital in Karachi.</p><p><strong>Study Design:  </strong>A case control study.</p><p><strong>Methods:  </strong>Three hundred and fifteen clinical isolates of Acinetobacter baumannii collected from different ICUs were evaluated during 1 year period. The isolates were identified by morphology, growth and biochemical characteristics, susceptibility to a panel of anti-microbial agents in disc diffusion assay and molecular characterization by PCR using glt A and gyr B genes.</p><p><strong>Results:  </strong>94% of Acinetobacter spp were detected as multi drug resistant (MDR) and sensitive to Polymixin B only. About 6% Acinetobacter spp were also MDR but sensitive to Polymixin B, Meropenem and Salbactum + Cefoperazone. All tested isolates exhibited differing resistance representation, as establish by medium incorporation – replica method, against different tested antibiotics, as follows: Amoxicillin – Cal-vulanic acid, Tazobactam, Ceftriaxone, Ceftazidime, Meropenem, Imipenem, Gentamicin, Amikacin, Chlo-ramphenicol, Cotrimoxazole, Tobramycin, Salbactam, Cefoperazone, Gentamicin and Amikacin. All the isolates of Acinetobacter baumannii were PCR positive for glt A and gyr B.</p><p><strong>Conclusions:  </strong>Acinetobacter baumannii is the most frequently isolated and alarming pathogen in the health care system specifically for the patients in intensive care units (ICUs). Its survival in hospital environment is because of tolerance the antibiotics and antiseptic pressures. Multi drug resistance made this pathogen the lethal pathogen of this century to infect debilitated patients. There is a strict need to monitor the surveillance of global clones at institutional and or intra-institutional level for accurate treatment, precise prevention and batter control.</p>

scholarly journals Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary

2017 ◽  
Vol 66 (6) ◽  
pp. 788-797 ◽  
Author(s):  
András Magyar ◽  
Béla Köves ◽  
Károly Nagy ◽  
András Dobák ◽  
Vinodh Kumar Adithyaa Arthanareeswaran ◽  
...  
Keyword(s):  
Antibiotic Resistance ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Care Hospital

scholarly journals Susceptibility of Clinical Isolates of Staphylococcus aureus to Ceftaroline

2021 ◽  
Author(s):  
Harsha Sreedharan ◽  
KB Asha Pai
Keyword(s):  
Staphylococcus Aureus ◽  
Tertiary Care Hospital ◽  
Methicillin Resistance ◽  
Descriptive Analysis ◽  
Tertiary Care ◽  
The United States ◽  
Clinical Isolates ◽  
Diffusion Method ◽  
Clinical Samples ◽  
Care Hospital

Introduction: Methicillin-Resistant Staphylococcus aureus(MRSA) infection is a major global healthcare problem, the prevalence of which varies from 25-50% in India. It is known to cause Skin and Soft tissue Infections (SSI), endovascular infections, endocarditis, pneumonia, septic arthritis, osteomyelitis, and sepsis. Vancomycin is the drug of choice for treating severe MRSA infections. Ceftaroline, a fifth-generation cephalosporin has been approved by the United States Food and Drug Administration (US FDA) for treating acute bacterial SSI caused by susceptible micro-organisms including MRSA, Community acquired respiratory tract infection, MRSA bacteremia and endocarditis. Aim: To assess the susceptibility of clinical isolates of S. aureusto ceftaroline, in a Tertiary Care Hospital. Materials and Methods: This prospective study was conducted in the Department of Microbiology of a Tertiary Care Hospital over a period of two months from June 2019 to July 2019. S.aureus isolates from various clinical samples were screened for methicillin resistance by disc diffusion method using cefoxitin disc and ceftaroline susceptibility of these isolates was assessed by E-strip method. The isolates were classified as ceftaroline susceptible, Susceptibility Dose Dependent (SDD) and ceftaroline resistant respectively as per CLSI guidelines. A descriptive analysis of the data was done and the results were presented as frequencies and percentages. Results: All the S.aureus isolates were found to be susceptible to ceftaroline. Methicillin Sensitive Staphylococcus aureus(MSSA) isolates had lower Minimum Inhibitory Concentration (MIC) when compared to MRSA. The highest MIC among MRSA was 0.5 μg/mL. Conclusion: Ceftaroline can be considered as an effective alternative for treatment of infections caused by MRSA.

Sign in / Sign up

Export Citation Format

Share Document